Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of autoimmune-inflammatory indications, oncology and liver diseases as well as sexual dysfunction. The Company’s lead drug candidate, Piclidenoson, is headed into Phase III trials for two indications, rheumatoid arthritis and psoriasis. Can-Fite’s liver cancer drug Namodenoson is in a Phase II trial for patients with liver cancer and is slated to enter another Phase II for the treatment of non-alcoholic fatty liver disease (NAFLD), the precursor to non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for hepatocellular carcinoma by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date.
Companies To Watch
XXII 1.39 +0.01 CKPT 10.25 +0.00 CPHR 2.9901 +0.0000 CFRX 1.40 -0.10 CRBP 6.45 -0.30 DMPI 2.20 -0.10 DVAX 5.70 +0.15 FBIO 3.95 +0.11 KERX 6.46 +0.04 MTNB 3.00 -0.03 MDGN 5.57 +0.17 MNOV 5.95 -0.10 MTFB 8.99 +0.59 PRQR 5.00 +0.05 STML 8.45 +0.10 SYN 0.6068 +0.0148 TGTX 12.05 +0.15 THLD 0.4693 +0.0093 TNXP 4.46 +0.11 VSTM 2.37 +0.00 ZIOP 6.29 -0.28 2017-05-26 16:01
- Tonix Pharmaceuticals to Present Additional Clinical Results of Military-Related PTSD Study at the 2017 American Society of Clinical Psychopharmacology Annual Meeting
- Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD
- Avenue Therapeutics Receives Notice of Allowance for a New Patent Application Covering Methods of Administration for Intravenous Tramadol